Oxytocin and vasopressin systems in obesity and metabolic health: Mechanisms and perspectives
Research output: Contribution to journal › Review › Research › peer-review
Standard
Oxytocin and vasopressin systems in obesity and metabolic health : Mechanisms and perspectives. / Ding, Cherlyn; Magkos, Faidon.
In: Current Obesity Reports, Vol. 8, No. 3, 2019, p. 301-316.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Oxytocin and vasopressin systems in obesity and metabolic health
T2 - Mechanisms and perspectives
AU - Ding, Cherlyn
AU - Magkos, Faidon
N1 - CURIS 2019 NEXS 252
PY - 2019
Y1 - 2019
N2 - Purpose of review: The neurohypophysial endocrine system is identified here as a potential target for therapeutic interventions toward improving obesity-related metabolic dysfunction, given its coinciding pleiotropic effects on psychological, neurological and metabolic systems that are disrupted in obesity.Recent findings: Copeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes. Plasma oxytocin is decreased in obesity and several other conditions of abnormal glucose homeostasis. Recent data also show non-classical tissues, such as myocytes, hepatocytes and β-cells, exhibit responses to oxytocin and vasopressin receptor binding that may contribute to alterations in metabolic function. Summary: The modulation of anorexigenic and orexigenic pathways appears to be the dominant mechanism underlying the effects of oxytocin and vasopressin on body weight regulation; however, there are apparent limitations associated with their use in direct pharmacological applications. A clearer picture of their wider physiological effects is needed before either system can be considered for therapeutic use.
AB - Purpose of review: The neurohypophysial endocrine system is identified here as a potential target for therapeutic interventions toward improving obesity-related metabolic dysfunction, given its coinciding pleiotropic effects on psychological, neurological and metabolic systems that are disrupted in obesity.Recent findings: Copeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes. Plasma oxytocin is decreased in obesity and several other conditions of abnormal glucose homeostasis. Recent data also show non-classical tissues, such as myocytes, hepatocytes and β-cells, exhibit responses to oxytocin and vasopressin receptor binding that may contribute to alterations in metabolic function. Summary: The modulation of anorexigenic and orexigenic pathways appears to be the dominant mechanism underlying the effects of oxytocin and vasopressin on body weight regulation; however, there are apparent limitations associated with their use in direct pharmacological applications. A clearer picture of their wider physiological effects is needed before either system can be considered for therapeutic use.
KW - Faculty of Science
KW - Insulin resistance
KW - Beta-cell function
KW - Energy exoenditure
KW - Neurohypophysis
KW - Substrate metabolism
KW - Vasopressin
U2 - 10.1007/s13679-019-00355-z
DO - 10.1007/s13679-019-00355-z
M3 - Review
C2 - 31240613
VL - 8
SP - 301
EP - 316
JO - Current Obesity Reports
JF - Current Obesity Reports
SN - 2162-4968
IS - 3
ER -
ID: 225375987